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Abstract
Background: p73, a p53 family member is a transcription factor that plays a role in cell cycle,
differentiation and apoptosis. p73 is regulated through post translational modifications and protein
interactions. c-Abl is the only known tyrosine kinase that phosphorylates and activates p73. Here
we have analyzed the role of Src family kinases, which are involved in diverse signaling pathways, in
regulating p73.
Results: Exogenously expressed as well as cellular Hck and p73 interact in vivo. In vitro binding
assays show that SH3 domain of Hck interacts with p73. Co-expression of p73 with Hck or c-Src
in mammalian cells resulted in tyrosine phosphorylation of p73. Using site directed mutational
analysis, we determined that Tyr-28 was the major site of phosphorylation by Hck and c-Src, unlike
c-Abl which phosphorylates Tyr-99. In a kinase dependent manner, Hck co-expression resulted in
stabilization of p73 protein in the cytoplasm. Activation of Hck in HL-60 cells resulted in tyrosine
phosphorylation of endogenous p73. Both exogenous and endogenous Hck localize to the nuclear
as well as cytoplasmic compartment, just as does p73. Ectopically expressed Hck repressed the
transcriptional activity of p73 as determined by promoter assays and semi-quantitative RT-PCR
analysis of the p73 target, Ipaf and MDM2. SH3 domain- dependent function of Hck was required
for its effect on p73 activity, which was also reflected in its ability to inhibit p73-mediated apoptosis.
We also show that Hck interacts with Yes associated protein (YAP), a transcriptional co-activator
of p73, and shRNA mediated knockdown of YAP protein reduces p73 induced Ipaf promoter
activation.
Conclusion: We have identified p73 as a novel substrate and interacting partner of Hck and show
that it regulates p73 through mechanisms that are dependent on either catalytic activity or protein
interaction domains. Hck-SH3 domain-mediated interactions play an important role in the
inhibition of p73-dependent transcriptional activation of a target gene, Ipaf, as well as apoptosis.
Background
p73 is a transcription factor that shares significant hom-
ology with the tumor suppressor protein p53 and medi-
ates cellular functions such as cell cycle arrest,
differentiation, senescence and apoptosis [1,2]. Alternate
promoter usage and splicing give rise to p73 variants dif-
fering at the N and C-terminus, p73 α and β forms being
the predominant transactivation competent forms [3,4].
p73 and p53 bind common response elements and trans-
activate an overlapping set of target genes, though with
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severe neurological, inflammatory and pheromonal
defects but lack spontaneous tumor formation [8]. Forced
expression of p73 activates target genes like p21, Bax, IGF
BP3, CyclinG, Mdm2, caspase-1, etc and promotes apop-
tosis in both p53 positive as well as negative cell lines
[1,5-7,9].
Cellular p73 protein is maintained at very low levels and
activation is controlled at transcriptional as well as post-
translational levels. p73 is induced in response to a range
of DNA damaging agents as well as during differentiation
of many cell types [10]. Multiple mechanisms like post-
translational modifications, protein-protein interaction
and sub-cellular compartmentalization regulate transacti-
vation potential and apoptosis inducing property of p73
[10,11]. Several viral and cellular proteins interact with
p73 and regulate its activity [3]. While some of the inter-
acting proteins enhance transactivation potential of p73
by stabilizing it [12-14], others inhibit transactivation
property of p73 [15-20]. p73 is also known to interact
with and cooperate with other transcription factors to reg-
ulate gene expression [9,21]. Interaction with c-Abl
through SH3 domain in response to DNA damage results
in phosphorylation at Tyr99, stabilization and activation
[12,22,23]. c-Abl can also activate p38 MAP kinase to
phosphorylate p73 leading to its stabilization [24].
Src family kinases (SFKs) are non receptor tyrosine kinases
involved in the regulation of diverse cellular functions like
proliferation, differentiation, survival, adhesion, motility
and angiogenesis [25]. Apart from a catalytic domain,
they possess SH2, SH3 and SH4 domains required for
sub-cellular targeting and protein interaction and there-
fore have cellular functions dependent on catalytic activity
as well as protein interaction domains [26,27]. Hck is a
SFK showing restricted expression in hematopoietic cells
of myeloid and monocytic lineage and in embryonic stem
cells [28-30]. It exists as two isoforms (p61 and p59 in
humans), which arise due to alternate translational start
sites [31]. Hck is activated in response to cytokines and is
an important component of signaling pathways in acti-
vated macrophages [32-34]. Hck levels increase during
differentiation of monocytes and it plays a role in phago-
cytosis, adhesion, respiratory burst, granule secretion and
apoptosis [35-37]. Several proteins like Cbl, Stat-3, WASP,
WIP, ELMO, ACK1 and C3G interact with Hck through its
SH3 domain [36-40]
The mechanisms that regulate stability and pro-apoptotic
activity of p73 are distinct from those used by p53 and
regulation by tyrosine phosphorylation has been shown
only for p73 [23]. Though initial studies described Tyr-99
as the major site of phosphorylation by cAbl, it has been
shown that several other tyrosine residues are also tar-
geted [41]. But thus far, no other tyrosine kinase has been
described to phosphorylate or regulate p73 activity. Hck
interacts with c-Abl and they modulate each other's activ-
ity [42]. Given the role of SFKs in mediating survival and
apoptotic pathways in cells, we investigated the role of
Hck in regulating p73 activity and function. Our results
identify p73 as a novel interacting partner and substrate of
Hck, and that Hck regulates p73 through kinase depend-
ent as well as independent functions. We also provide evi-
dence for functional interaction between p73 and Hck
leading to regulation of p73 induced apoptosis.
Results
Hck interacts with p73α
We explored the possibility of p73 interacting with Hck in
vivo in co-immunoprecipitation experiments. p73 was
detected in Hck immunoprecipitates from cells expressing
both Hck and p73, but not in cells expressing p73 alone
suggesting their interaction in mammalian cells (Fig. 1A).
p73 has polyproline sequences that could serve as inter-
acting motifs for SH3 domain containing proteins. To
determine whether Hck and p73 form a complex through
SH3-polyproline mediated interaction, in vitro binding
experiments were carried out using glutathione-S-trans-
ferase (GST) fusion proteins. Recombinant fusion protein
of GST with SH3 domain of Hck (GST-SH3 Hck) bound
to Glutathione Sepharose beads was incubated with
lysates of Cos1 cells transfected with p73α and p73δ. p73δ
is the shortest isoform which lacks the entire C-terminus
including the SAM domain[3]. p73α and p73δ bound to
GST-SH3-Hck and not with GST alone (Fig. 1B). Further,
recombinant fusion protein of SH3 domain mutant
(W93A) disabled for interaction (GST-mSH3 Hck) and
GST-SH3-Hck were incubated with lysates of Cos1 cells
transfected with p73α. p73α bound to GST-SH3-Hck and
not to GST or GST-mSH3-Hck (whose levels were compa-
rable) (Fig. 1C). It has been shown that upon dimethyl
sulfoxide (DMSO) treatment of HL-60 cells, both mRNA
and protein levels of p73α increase in a time dependent
manner [43]. Hck levels are also known to increase under
these conditions [44]. To examine whether endogenous
p73 interacts with Hck under these conditions, we sub-
jected lysates of differentiated HL-60 cells to immunopre-
cipitation using Hck antibody. Western blotting with p73
antibody showed that p73α was co-immunoprecipitated
with Hck and not with control antibody (Fig. 1D). Our
results suggest that endogenous Hck and p73 interact
under physiological conditions.
Hck co-expression results in phosphorylation of p73
Since p73 interacted with Hck, the possibility of p73
being a substrate of Hck in vivo was explored. Cos1 cells
were transfected with HA-p73α expression construct with
and without Hck and whole cell lysates subjected to west-
ern blotting with anti-phosphotyrosine antibody. WhenPage 2 of 18
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seen on the polypeptide corresponding to p73 in mobility
as detected by reprobing the blot using p73 antibody (Fig.
2A). Cells transfected with p73 or Hck alone did not show
any corresponding phosphotyrosine containing peptides.
Phosphorylation of p73 was dependent on kinase activity
of Hck since co-expression of a catalytically inactive
mutant KD-Hck (K269E) did not show tyrosine-phospho-
rylated polypeptide at the corresponding position (Fig.
2A). To confirm phosphorylation of p73 more directly,
p73 was immunoprecipitated from cells expressing p73α
and Hck. Phosphorylated p73 could be detected in immu-
noprecipitates of p73α with Hck over-expression whereas
it was not observed with over-expressed KD-Hck (Fig. 2B,
upper panel). Hck also phosphorylated p73β, dependent
on its kinase activity (data not shown). These results sug-
gested that Hck expression could induce tyrosine phos-
phorylation of p73α and β in vivo. To check whether Hck
phosphorylation on p73 is a direct event, in vitro phos-
phorylation assay was carried out. Recombinant GST and
GST-p73α bound to glutathione-Sepharose beads were
incubated with purified Hck enzyme and γ32P ATP. Pro-
teins were analyzed by SDS-PAGE, stained and the gel
dried for phosphor imaging. Hck phosphorylated GST-
p73α and not GST alone (Fig. 2C, right panel). Protein
expression was visualized by commassie staining of the
Hck interacts with p73α in vitro and in vivoFigure 1
Hck interacts with p73α in vitro and in vivo. (A) Cos1 cells transiently expressing HA-p73α alone or with Hck were 
immunoprecipitated with control rabbit IgG (C) or Hck polyclonal antibody. The immunoprecipitates were resolved by SDS-
PAGE and subjected to western blotting to detect p73 and Hck. (B) GST fusion proteins bound to Glutathione-Sepharose 
beads were incubated with lysates of Cos1 cells overexpressing p73α and p73δ. Bound proteins were subjected to western 
blotting to detect p73. (C) GST-SH3 Hck and GST-mSH3 Hck recombinant fusion proteins bound to Glutathione-Sepharose 
beads were incubated with lysates of Cos1 cells overexpressing p73α and bound proteins were subjected to western blotting 
with p73 antibody. (D) Lysates of differentiated HL-60 cells (DMSO 1.25%) were immunoprecipitated with control rabbit IgG 
or Hck antibodies and subjected to western blotting for p73 and Hck. (WCL indicates whole cell lysate).Page 3 of 18
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Hck phosphorylates p73α in vivo and in vitroFigure 2
Hck phosphorylates p73α in vivo and in vitro. (A) Whole cell lysates prepared from Cos1 cells transfected with HA-p73α 
(1.6 μg) with and without Hck (0.4 μg) expression constructs in the ratio of 4:1 were subjected to immunoblotting with pTyr, 
p73 and Hck antibodies. (B) Cos1 cells transfected with indicated expression constructs were subjected to immunoprecipita-
tion with p73 antibody and immunoprecipitates analyzed for pTyr, p73 and Hck by western blotting. The amount of DNA was 
kept constant by addition of control vector pcDNA3. (C) Purified Hck protein (80 nM) was incubated with GST, GST-p73α 
and alone with γ32P-ATP for 30 minutes at 37°C in an in vitro kinase assay. The proteins were analyzed by SDS-PAGE and 
stained with commassie blue (left panel). The gel was then dried and phosphorylated proteins visualized by phosphor imaging 
(right panel). (D) Western blot showing the endogenous protein levels of p73 and Hck upon differentiation with DMSO in HL-
60 cells. Tubulin expression was determined as a loading control. (E) Endogenous p73 gets phosphorylated on tyrosine upon 
activation of Hck. Western blot showing the phosphotyrosine content of cellular proteins and levels of endogenous p73 and 
Hck upon HgCl2 treatment in differentiated HL-60 cells (left panel). Lysates of diferentiated HL-60 cells treated with or with-
out HgCl2 were subjected to immunoprecipitation with control (rabbit IgG) or p73 (rabbit polyclonal) antibody and western 
blotting performed with anti-phosphotyrosine antibody (right panel, upper portion) Immunoprecipitated p73 is shown in right 
panel, lower portion.
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showed that Hck could directly phosphorylate p73α.
Endogenous p73 gets tyrosine phosphorylated upon 
activation of Hck
Treatment of myelomonocytic cell lines with mercuric
chloride (HgCl2) has been shown to specifically activate
Hck, and has been used to identify substrates of Hck
[36,45,46]. Treatment of HL-60 cells with DMSO showed
an increase in protein levels of both p73α and Hck (Fig.
2D). To find out whether endogenous p73 gets tyrosine
phosphorylated upon activation of Hck, HL-60 cells were
differentiated for 48 hours with DMSO and then sub-
jected to HgCl2 treatment. The lysates were immunopre-
cipitated with p73 and control antibody. It was observed
that endogenous p73 gets tyrosine phosphorylated upon
activation of Hck as determined by western blotting with
phosphotyrosine antibody (Fig. 2E, right panel). The left
panel of Fig. 2E shows the western blots of whole cell
lysate (WCL) with phosphotyrosine, p73 and Hck anti-
bodies.
Hck phosphorylates p73α predominantly on Tyr28
To identify the site of phosphorylation on p73α by Hck,
different tyrosine mutants were constructed by PCR based
site directed mutagenesis in which tyrosine residues that
are predicted targets for Src family tyrosine kinases (SFKs)
were mutated to phenylalanine. Cos1 cells were trans-
fected with p73α or Y28F-p73α, Y121F-p73α, Y309F-
p73α, Y355-356F-p73α in the presence of Hck and whole
cell lysates subjected to western blotting with pTyr, p73
and Hck antibodies. All the mutants except Y28F-p73α
showed phosphorylation comparable to that seen on WT-
p73α (Fig. 3A). Y28F-p73α was compromised considera-
bly in phosphorylation by Hck (Fig. 3A). This was not due
to lower level of expression because p73 and Hck were
comparable as determined by reprobing the blot with
anti-p73 and anti-Hck antibody (Fig. 3A). c-Abl is a non-
receptor tyrosine kinase which phosphorylates p73α on
Y99 residue and activates it [23]. Hck induced phosphor-
ylation of Y99F-p73α as well as WT-p73α while Y28F-
p73α was particularly compromised in phosphorylation
(Fig. 3B). c-Src co-expression also resulted in p73α phos-
phorylation predominantly on Y28 residue whereas
expression of KD Src did not result in p73 phosphoryla-
tion (Fig. 3C). Taken together, our results suggest a novel
site (Y28) of phosphorylation on p73α by Src family
kinases, which is different from c-Abl mediated phospho-
rylation of p73 on Y99 residue.
Hck co-expression stabilizes p73
To determine whether Hck affects p73 protein levels, Hela
cells were transfected with p73α alone or with Hck and
whole cell lysates subjected to immunoblotting with anti
p73 antibody. Co-expression of Hck but not KD-Hck
showed higher p73α protein levels (Fig. 4A). Hck also
increased the protein levels of Y28F-p73α, which sug-
gested that increase in p73α protein level is not depend-
ent on Y28 phosphorylation. The same blot was probed
for Hck and GFP that was used as transfection efficiency
control (Fig. 4A). These results suggest that Hck could
increase the p73 protein levels in a kinase dependent
manner. To examine whether p73 increase seen upon co-
expression with Hck is due to effect on its stability, levels
of p73 protein were determined in the presence of
cycloheximide. p73 levels dropped significantly by 9
hours of cycloheximide treatment but did not change sig-
nificantly when co-expressed with Hck (Fig. 4B) suggest-
ing that Hck increases p73 protein stability.
Sub-cellular localization of Hck and p73
Since Hck is a non-receptor tyrosine kinase known to
localize to plasma membranes, Golgi and in the cyto-
plasm [47-50] and p73 shows nucleo-cytoplasmic
exchange, we investigated sub-cellular distribution of
p73α upon co-expression with Hck by biochemical frac-
tionation of transfected Cos1 cells. Phosphorylated p73α
was present predominantly in cytosolic fraction upon Hck
over expression (Fig. 5A). When co-expressed with Hck,
there was 2.3-fold increase in cytosolic p73 as compared
to the cytosolic fraction of p73α transfected alone (Fig.
5A) suggesting that p73 is stabilized in the cytosolic frac-
tion. Surprisingly, we observed that a fraction of Hck
localized to the nucleus. Cross-contamination of the frac-
tions was ruled out by probing for tubulin and PARP.
Unlike other Src family kinases such as Src, Lyn and Fyn
[51-55], no evidence is available for nuclear localization
of Hck. It was therefore important to evaluate that pres-
ence of Hck in the nucleus is not a feature of exogenously
expressed protein. We determined the sub-cellular distri-
bution of endogenous Hck in a myeloid cell line HL-60.
As shown in Fig. 5B, endogenous Hck distributed to both
nuclear and cytosolic compartments as evidenced by sub-
cellular fractionation. To confirm that sub cellular frac-
tions were not contaminated, the fractions were analysed
by western blotting for Calnexin (an ER protein, present
in post nuclear fraction) and PARP (present only in
nuclear fraction). The presence of endogenous Hck in the
nucleus was confirmed by indirect immunofluorescence
assay. HL-60 cells were differentiated with 10 ng/ml of 12-
O-tetradecanoylphorbol-13-acetate (TPA), which allows
cells to adhere to the coverslips. After 24 hours, cells were
fixed and immunostained with Hck antibody and ana-
lysed by confocal microscopy. The middle section passing
through the nucleus was analysed for determination of
Hck localization. As shown in Fig. 5C, endogenous Hck
localized to the nucleus. The cells were also stained with-
out primary antibody for control.Page 5 of 18
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Tyr-28 is the major site of phosphorylation on p73 upon Hck co-expressionFigure 3
Tyr-28 is the major site of phosphorylation on p73 upon Hck co-expression. (A, B) Cos1 cells transfected with indi-
cated combinations of p73 and Hck plasmids were analyzed by western blotting for pTyr. The same blot was reprobed for p73 
and Hck. (C) Src tyrosine kinase phosphorylates p73α on Tyr-28 residue. Cos1 cells transfected with p73α, Y28F-p73α or c-
Src and KD-Src were subjected to western blotting for pTyr, p73 and Src.
BMC Molecular Biology 2007, 8:45 http://www.biomedcentral.com/1471-2199/8/45Hck suppresses transactivation of p73 targets
Since interacting proteins and modifications affect the
transactivation ability of p73, we determined if Hck co-
expression influences p73 activity. We first compared the
ability of Hck and c-Abl to regulate p73 activity using
PG13 construct that has multiple binding sites for p73. c-
Abl enhanced p73β activity but Hck co-expression
resulted in inhibition of its activity (Fig. 6A). This effect of
Hck was also tested using Ipaf promoter. Ipaf, an activator
of caspase-1, was recently identified as a p53 target gene
induced by DNA damage and was shown to play a role in
p53 mediated apoptosis [56]. p73α even at low level (2 ng
of plasmid) could strongly transactivate expression of a
reporter gene cloned downstream of the Ipaf promoter
(Fig. 6B). It was found that Hck repressed activation of
Ipaf promoter reporter construct by p73α (Fig. 6B). Coex-
pression of kinase dead (KD) mutant of Hck was also able
to repress p73α-mediated transactivation similar to wild
type (WT) Hck when tested using Ipaf reporter construct
(Fig. 6B). Overexpression of Hck also repressed p73α-
induced transactivation of MDM2 promoter, which was
independent of kinase activity of Hck, as co-expression of
KD mutant of Hck repressed p73α mediated transactiva-
tion similar to WT-Hck (Fig. 6C).
Functional SH3 domain of Hck is required for inhibition of 
p73 transcriptional activity
Since Hck inhibited the transcriptional activity of p73α
isoform in a kinase-independent manner, we explored the
possibility of the involvement of SH3 domain. Towards
this end, a critical tryptophan was mutated to alanine
(W93A). This mutation in Hck abolished the binding of
SH3 domain to proline rich sequences of proteins as well
as enhanced its kinase activity [39]. W93A-Hck (mSH3-
Hck) was transfected in the presence and absence of p73α
along with Ipaf-CAT reporter construct. mSH3-Hck was
not able to inhibit p73α mediated transcriptional activity
of Ipaf promoter whereas WT-Hck showed inhibition (Fig.
6D), suggesting that this inhibition is dependent on func-
tional SH3 domain of Hck. To analyse if this property was
unique to Hck, the effect of Src on Ipaf-promoter transac-
tivation was examined. HeLa cells were transfected with
p73α (2 ng) and c-Src or Hck (200 ng each) along with
Ipaf-CAT promoter (200 ng) and cell lysates subjected to
reporter activity assay. c-Src inhibited p73α mediated
transactivation by 26.21% as compared to Hck which
inhibited the activity by 60% (Fig. 6E). These results sug-
gest that Hck is a more potent inhibitor of p73 induced
Ipaf-promoter transactivation as compared to c-Src indi-
cating the difference in properties between the two mem-
bers of Src family kinases.
The effect of Hck on p73 induced endogenous gene
expression was examined by semi-quantitative reverse
transcriptional (RT)-PCR analysis in HeLa cells. Hck and
mSH3-Hck were transfected with p73α in a ratio of 6.5:1
and total RNA prepared. These conditions were used to
ensure that all p73 expressing cells also co-express Hck.
Ectopic expression of p73α resulted in an increase in
endogenous Ipaf mRNA levels, and co-expression with
WT-Hck resulted in inhibition of expression (Fig. 6F). Co-
expression of mSH3-Hck with p73α did not inhibit p73α
induced Ipaf mRNA levels (Fig. 6F). This was also
observed with endogenous MDM2 mRNA levels where
coexpression of WT-Hck inhibited MDM2 gene expres-
sion significantly and mSH3-Hck coexpression with p73α
did not inhibit p73α induced MDM2 mRNA levels. These
results suggested that functional SH3 domain of Hck is
indispensable for repression of p73 transcriptional activ-
ity. We assessed the ability of Hck to regulate expression
of PUMA, a well-known target of p73. RT-PCR analysis
Hck stabilizes p73α dependent on its kinase activityFigure 4
Hck stabilizes p73α dependent on its kinase activity. 
(A) Hela cells transfected with GFP (50 ng) and Hck or 
KDHck(200 ng) in the presence of p73α or Y28F-p73α (50 
ng) were subjected to western blotting for p73, Hck and 
GFP. GFP was used as a transfection efficiency control. (B) 
Hela cells transfected with p73α or p73α and Hck together 
were treated with cycloheximide (50 μg/ml), harvested at the 
indicated time periods and immunoblotted for p73 and tubu-
lin. The amount of DNA in transfections was kept constant 
by the addition of control vector pcDNA3.Page 7 of 18
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Sub-cellular localization of Hck and p73αFigure 5
Sub-cellular localization of Hck and p73α. (A) Cos1 cells transiently transfected with p73α or Hck and p73α were frac-
tionated into nuclear and cytosolic fractions and analysed by immunoblotting for pTyr, p73 and Hck. The purity of nuclear and 
cytosolic fractions was confirmed by immunoblotting for PARP and α-tubulin. (B) Endogenous Hck in HL-60 cells localizes to 
both cytosolic and nuclear fractions. HL-60 cells were fractionated into nuclear and cytosolic (post nuclear fraction) fractions 
and immunoblotted using Hck antibody. The purity of fractions was confirmed by immunoblotting with PARP and Calnexin. 
WCL indicates whole cell lysates. (C) Localization of endogenous Hck in the nucleus by immunostaining. HL-60 cells were 
immunostained with Hck antibody after 24 hours of differentiation by TPA (10 ng/ml) and analysed by confocal microscopy. 
The image shown is the central section passing through nucleus. The cells were also stained without primary antibody, which 
served as a control.
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Hck inhibits the transcriptional activity of p73α and β isoforms, dependent on its SH3 domainFigure 6
Hck inhibits the transcriptional activity of p73α and β isoforms, dependent on its SH3 domain. (A-D) Hela cells 
transfected with pCMV-βgal (50 ng) and different promoter constructs (100 ng) along with p73α or p73β and Hck or KD-Hck 
were subjected to either luciferase or CAT activity measurements. The amount of DNA was kept constant in all transfections 
to 400 ng by adding pcDNA3. Hck, KD-Hck, mSH3-Hck and c-Abl plasmids were used at 100 ng for different promoter con-
structs. The amount of p73α used was 2 ng for Ipaf-CAT promoter and 50 ng for MDM2-Luc promoter. The amount of p73β 
used was 10 ng for PG13-Luc promoter. Relative reporter activities were calculated after normalizing with β-galactosidase 
activities. Data presented here are mean ± S.D. of at least three independent experiments, *p < 0.01.(E) Effect of c-Src on p73 
induced Ipaf promoter transctivation. HeLa cells transfected with Ipaf promoter construct along with p73α (2 ng) and c-Src or 
Hck (100 ng) were subjected to CAT activity measurements. Data presented here are mean ± S.D. of at least three independ-
ent experiments, *p < 0.05, **p < 0.01. (F, G) Total RNA isolated from Hela cells transfected with HA-p73α (200 ng) or Hck 
(1300 ng) and mSH3 Hck (1300 ng) were subjected to RT-PCR analysis for Ipaf, MDM2 and PUMA gene expression. p73α and 
Hck mRNA levels were determined for transfection efficiency control whereas GAPDH mRNA levels were used as an internal 
control.
BMC Molecular Biology 2007, 8:45 http://www.biomedcentral.com/1471-2199/8/45showed that p73α expression upregulates expression of
PUMA in HeLa cells. Upon co-expression of Hck with
p73α, PUMA expression was not altered under the condi-
tions where Ipaf gene expression was repressed (Fig. 6G).
This result shows that Hck may regulate endogenous p73
targets selectively.
Inhibition of p73α induced apoptosis by Hck
p73α expression induces apoptosis in osteosarcoma cell
line SAOS2 that is p53-/- [5]. We wished to determine
whether repressive effect of Hck on p73 activity is reflected
also in its ability to suppress apoptosis. We examined the
effect of Hck expression on p73α-induced apoptosis in
SAOS2 cell line. p73α was overexpressed with and with-
out Hck and cells were scored for apoptosis after immu-
nostaining for p73 and Hck expression. p73α alone
induced apoptosis in 33% of expressing cells but co-
expression with Hck resulted in apoptosis of only 15% of
expressing cells (Fig. 7A). A functional SH3 domain in
Hck was required for inhibiting p73-induced apoptosis
since the W93A-Hck construct did not show any inhibi-
tory effect. This property was independent of Hck kinase
activity as seen by the ability of KD Hck to inhibit p73-
induced apoptosis (Fig. 7A). The morphology of single
and dual expressing cells is shown in Fig. 7B. Further, to
assess downstream events of apoptosis, cleaved caspase-3
levels were determined by immunostaining. A large
number of p73α expressing cells showed increased stain-
ing of cleaved caspase-3, which is a hallmark for apoptosis
(Fig. 7C). Co-expression of Hck along with p73α showed
significant reduction in number of cells expressing cleaved
caspase-3, whereas mSH3-Hck coexpression did not affect
the number of cells with cleaved caspase-3 in SAOS2 cells
(Fig. 7C).
The effect of Hck on p73 induced Ipaf gene expression in
SAOS-2 cells was examined. When Hck was co-expressed
with p73α, Ipaf expression was reduced significantly (Fig.
7D). This repression was independent of kinase activity of
Hck but dependent on functional SH3 domain of Hck
(Fig. 7D). We determined the effect of Y28F-p73α muta-
tion on its ability to transactivate gene expression. Expres-
sion of p73α or Y28F-p73α mutant in SAOS2 cells
resulted in an increased expression of Ipaf gene as deter-
mined by RT-PCR (Fig. 7E). Co-expression of Hck sup-
pressed p73α-induced as well as Y28F mutant-induced
expression of Ipaf mRNA (Fig. 7E). To determine whether
some other target of p73 is affected by Y28F mutation, we
analysed the induction of 14-3-3σ mRNA (known to be
induced by p73α) [57] by p73α as well as by Y28F mutant
(Fig. 7E). Induction of 14-3-3σ mRNA was seen upon
expression of p73α as well as Y28F mutant. Interestingly,
there was no suppression of p73α or Y28Fp73α mutant
induced 14-3-3σ mRNA by Hck (Fig. 7E). These results
suggest that the suppressive effect of Hck on p73-induced
gene expression is promoter specific as was also observed
in HeLa cells.
Since Hck inhibited p73 induced promoter activation as
well as gene expression, this study was also extended to
check the ability of Hck to inhibit apoptosis induced by
cisplatin, an anti cancer drug known to mediate apoptosis
by activation of p73 [12]. SAOS2 cells were transfected
with GFP, WT-Hck or mSH3-Hck and immunostained for
expressing cells after cisplatin treatment. Quantitation of
apoptosis in expressing and nonexpressing cells showed
that Hck expression protected 47% of cells from cisplatin
induced apoptosis (Fig. 8A). Neither GFP expression nor
mutant SH3 Hck expression inhibited this apoptosis. The
protein levels of p73α, Hck and mSH3-Hck were also
determined upon cisplatin treatment which is shown in
Fig. 8B. The morphology of Hck expressing cells is shown
in Fig. 8C.
YAP interacts with Hck and is required for p73-induced 
activation of Ipaf promoter
In an attempt to elucidate the mechanism by which Hck
inhibits p73 activity in a target specific manner, we tested
the possible involvement of YAP, a molecule that binds to
and selectively regulates p73 dependent transactivation
[58,59]. YAP was first identified as the Src family kinase
Yes, interacting protein [60]. We explored the possibility
of YAP interacting with Hck in vivo in co-immunoprecipi-
tation experiments. YAP was detected in Hck immunopre-
cipitates from cells expressing both Hck and YAP and not
with control antibody (Fig. 9A). The ability of Hck to
interact with YAP was tested in vitro using GST fusion pro-
teins. YAP interacted with GST-SH3-Hck domain and not
with GST-mSH3-Hck domain (Fig. 9B).
The role of YAP in p73α mediated Ipaf promoter transac-
tivation was determined by knock down of YAP using
RNAi strategy. YAP shRNA I, II, III and control shRNA I
and II were transfected with GFP-YAP in HeLa cells in the
ratio of 4:1 and whole cell lyastes subjected to immunob-
lotting with GFP antibody. YAP shRNA I, II and III inhib-
ited the expression of GFP-YAP by 90%, 85% and 71%,
respectively, as compared to control shRNA I (Fig. 9C). As
can be seen in Fig. 9C, (lower panel), transfection effi-
ciency was comparable as determined by GFP blot which
was used as an efficiency control. To check the role of
endogenous YAP in p73α-induced Ipaf promoter transac-
tivation, YAP shRNA I, II and control shRNA I were trans-
fected with and without p73α along with Ipaf-CAT
promoter construct and CAT assays performed after 36
hours of transfection. YAP shRNA I and II significantly
inhibited p73α mediated Ipaf-promoter transactivation
(P < 0.05) (Fig. 9D). These results suggest that endog-
enous YAP is required for p73α-induced activation of Ipaf
promoter.Page 10 of 18
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Hck inhibits p73α-induced apoptosisFigure 7
Hck inhibits p73α-induced apoptosis. (A). SAOS-2 cells transfected with p73α and Hck, mSH3-Hck or KD-Hck in the 
ratio of 1:3 were immunostained for p73 and Hck and the percentage of apoptotic cells was scored among expressing and non-
expressing cells using morphological criteria. Data represent mean ± S.D. of at least three independent experiments performed 
on duplicate coverslips. (B) Panels show the morphological features of p73 and Hck expressing cells. Arrowhead shows apop-
totic cells and arrows indicate healthy cells. (C) SAOS-2 cells transfected with p73α and Hck or mSH3-Hck in the ratio of 1:3 
were immunostained for p73 and cleaved caspase-3 expression. (D) Total RNA isolated from SAOS-2 cells transfected with 
HA-p73α (200 ng) with or without Hck (1300 ng), mSH3 Hck (1300 ng) and KD Hck (1300 ng) were subjected to RT-PCR 
analysis as described in Fig. 7E. (E) p73α transactivation function is independent of Tyr-28 phosphorylation. RT-PCR analysis 
was carried out using RNA isolated from SAOS-2 cells after transfection with indicated expression constructs. Expression lev-
els of gene products were determined using appropriate primers. (UT indicates untransfected).
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Hck inhibits cisplatin induced apoptosisFigure 8
Hck inhibits cisplatin induced apoptosis. (A) SAOS2 cells transfected with GFP, Hck or mSH3 Hck (400 ng) were treated 
with 50 μM cisplatin (CDDP) for 24 hours and immunostained for Hck. The percentage of apoptotic cells was scored among 
expressing and non-expressing cells using morphological criteria. Data represent mean ± S.D. of at least three independent 
experiments. (B) SAOS2 cells transfected with Hck or mSH3 Hck (400 ng) were treated with 50 μM cisplatin (CDDP) for 24 
hours and whole cell lysates were subjected to western blotting with p73 (mouse monoclonal, Imgenex) and Hck antibody. 
Tubulin was used as loading control. (C) Panels show the expression of GFP, Hck and mSH3 Hck expressing cells.
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Hck interacts with YAP and requirement of YAP for transactivation of Ipaf by p73Figure 9
Hck interacts with YAP and requirement of YAP for transactivation of Ipaf by p73. (A) Cos1 cells transiently 
expressing GFP-YAP with Hck were immunoprecipitated with control rabbit IgG (C) or Hck polyclonal antibody. The immuno-
precipitates were resolved by SDS-PAGE and subjected to western blotting to detect YAP and Hck. (B) Extract of Cos1 cells 
transfected with GFP-YAP was incubated with GST, GST-SH3Hck, GST-mSH3-Hck recombinant proteins bound to Glutath-
ione Sepharose beads. Proteins bound to these beads were immunoblotted with GFP and GST antibodies. (C) YAP-shRNA 
downregulates GFP-YAP expression. Hela cells transfected with GFP-YAP (50 ng) with either control shRNA I and II (200 ng) 
or YAPshRNA I, II and III (200 ng) subjected to immunoblotting with anti-GFP antibody. GFP (50 ng) was used as transfection 
efficiency control. (D). Effect of YAP shRNA on p73α mediated Ipaf promoter transactivation. HeLa cells transiently trans-
fected with YAPshRNA I, II (200 ng) or control shRNA I (200 ng) in the presence or absence of p73α (2 ng) along with Ipaf-
CAT promoter construct (150 ng) and pCMV-β Gal (50 ng) were subjected to CAT activity measurements.
BMC Molecular Biology 2007, 8:45 http://www.biomedcentral.com/1471-2199/8/45Discussion
The present study identifies p73 as a substrate and inter-
acting partner of the Src family kinase, Hck. In vitro studies
using a GST fusion protein suggest that p73α could inter-
act directly with SH3 domain of Hck. Hck represses the
transcriptional activity of p73α. This repression was
observed under conditions where c-Abl co-expression
showed enhanced transactivation by p73 indicating that
c-Abl and Hck have opposing influence on the function of
p73 as a transcriptional activator. This repression was
independent of the catalytic activity of Hck but required
its SH3 domain. The effect of Hck on p73 activity was also
observed at the level of endogenous Ipaf and MDM2 gene
expression but did not influence two other known targets
of p73, PUMA and 14-3-3σ. The selective regulation of
p73 targets by Hck suggests a distinct role for Hck in vivo
with respect to modulation of expression of certain genes.
Apoptosis induced by exogenously expressed, as well as
endogenous p73, was inhibited by Hck, dependent on its
SH3 domain protein interaction function. This property
of Hck may therefore be a consequence of its ability to
repress target gene induction by p73.
Hck mediated inhibition of p73 activity may be effected
by direct interaction between these two proteins in vivo, or
by the involvement of a Hck interacting protein that is
required for p73 dependent transcriptional activation.
Endogenous as well as exogenously expressed Hck has
earlier been shown to localize to plasma membrane,
Golgi, secretory granules, nongranular membranes and
cytosol [47-50]. Most intracellular functions of Src family
kinases have been attributed to their localization to the
plasma membranes and cytosolic compartments. More
recently tyrosine kinases involved in receptor mediated
signaling pathways have been shown to be present in the
nucleus and their role in influencing activity of transcrip-
tion factors has been described [54,61]. Our results sug-
gest that both exogenously expressed as well as
endogenous Hck is present to some extent in nuclear com-
partment of cells. These observations raise the possibility
that the inhibition of p73 transcriptional activity by Hck
is mediated at least in part by the fraction of Hck present
in the nucleus. Cytoplasmic sequestration of p73 by Hck
is not likely to explain inhibition of p73 activity by Hck
because the level of p73 in the nucleus (which is likely to
be the transcriptionally active component) does not
decrease upon co-expression of Hck. Hck interaction with
p73 directly could alter its ability to bind or transactivate
a set of targets selectively.
Our results also show that Hck interacts with YAP, a tran-
scriptional co-activator, which imparts target selectivity to
p73. Since YAP was required for maximal activation of
Ipaf promoter by p73, it is possible that Hck mediates
repression of p73 transcriptional activity through its abil-
ity to interact with YAP. Based on the ability of p73δ to
interact with Hck and not with YAP [62], we can infer that
Hck and YAP bind to different sequences on p73. Forma-
tion of multimolecular complex, whereby both Hck and
YAP interact with p73, could be responsible for Hck caus-
ing selective repression of p73 target genes. Since Hck can
bind to YAP or to p73 through its single SH3 domain, an
alternate possibility is that its interaction with YAP may
alter the ability of YAP to transactivate p73 targets.
Phosphorylation of p73 by c-Abl at Y99 results in its acti-
vation [23]. Our study shows that Hck predominantly tar-
gets a tyrosine in the transactivation domain (Y28). This
difference in target site beween Hck and c-Abl rules out
the possibility of Hck expression resulting in p73 phos-
phorylation through activation of c-Abl, although Hck is
known to activate c-Abl [42]. This modification (Y28
phosphorylation) did not influence the activity of p73
because Y28F mutant showed the same level of activation
of Ipaf promoter as WT p73. Hck inhibited Ipaf gene
expression induced by p73α as well as Y28F mutant. We
also demonstrated that this modification is not a unique
property of Hck, since c-Src expression also resulted in
predominant phosphorylation of p73 at Y28. In addition,
Hck also targets other tyrosine residues (which we have
not specifically identified) because Y28 mutant was not
totally deficient in phosphorylation.
p73 stabilization has generally been shown to reflect in an
increase in its activity [12-14,24]. Our study showed that
over- expression of Hck results in stabilization of p73 pro-
tein, dependent on its kinase activity, but this does not
lead to an increase in p73 activity. Similarly, it has been
reported earlier that interaction of p73 with MDM2 results
in p73 stabilization but inhibition of p73 transcriptional
activity [63]. Our results also show that activation of
endogenous Hck results in tyrosine phosphorylation of
p73. p73 protein levels increase upon differentiation of
mylemonocytic cells ([43] and present study). Under
these conditions of differentiation, Hck levels and activity
are also known to increase. Hck activity mediated signal-
ing may therefore contribute to enhanced protein levels of
endogenous p73 upon differentiation. Upon cell fraction-
ation, we observed that Hck co-expression enhanced p73
protein levels only in the cytosolic fraction, but not in the
nuclear fraction. Phosphorylated p73 was essentially seen
in the cytosolic fraction. p73 localized to nuclear and
cytoplasmic compartments may have independent cellu-
lar functions just as does p53 [64-66]. Since phosphoryla-
tion at Y28 by Hck does not appear to play a significant
role in its stability, it is likely that other mechanisms con-
tribute to p73 stabilization dependent on the kinase activ-
ity of Hck. Recently, Fyn, a Src family kinase was shown to
negatively regulate Itch by tyrosine phosphorylation,
impairing its ubiquitinating activity [67]. Since Itch regu-Page 14 of 18
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is also possible that SFKs may indirectly regulate p73 by
preventing its degradation. We have yet to determine the
role of p73 stabilized by the kinase activity of Hck in the
cytoplasmic compartment.
SFKs modulate diverse signaling cascades dependent on
their ability to interact with and phosphorylate various
target proteins. In some contexts kinase and adaptor func-
tions can act independently to effect downstream signal-
ing. It therefore, appears that stabilization, which is
catalytic activity dependent and suppression of apoptosis,
which is SH3 domain interaction dependent, are inde-
pendent effects of Hck on p73. The functional significance
of Y28 phosphorylation of p73 is not clear at present and
would require further investigation.
Conclusion
In conclusion, our results show that the tyrosine kinase
Hck interacts with p73α physically and functionally. Hck
and c-Src phosphorylate p73α at Tyr-28, a novel site of
phosphorylation located in the transcriptional activation
domain. Transcriptional activity of p73 towards certain
target genes is selectively inhibited by Hck independent of
its kinase activity. Hck-SH3 domain mediated interactions
play an important role in the inhibition of p73-dependent
transcriptional activation of target genes as well as apop-
tosis.
Methods
Cell culture and transfections
HeLa, Cos1, and human osteosarcoma SAOS-2 cells were
grown in Dulbecco's modified eagle medium supple-
mented with 10% fetal bovine serum and antibiotics. HL-
60 cells were maintained in RPMI 1640 medium with
heat- inactivated 10% fetal bovine serum and antibiotics.
Cultures were maintained in a humidified 37°C incuba-
tor with 5% CO2. Transient transfections of HeLa and
SAOS-2 were performed with LipofectAMINE Plus reagent
according to the manufacturer's recommendations (Invit-
rogen). For transfection of Cos1 cells cationic lipid
DHDEAB was used as described [50].
Plasmid constructs and antibodies
The mammalian expression plasmids used were: hemag-
glutinin (HA) epitope-tagged p73α or p73β in pcDNA3
(gift from Dr. Gerry Melino, University of Rome, Italy),
Human p59 Hck in pcDNA6 (gift from Dr. Todd Miller,
State University of New York, Stony Brook), c-Src and
K297R-c-Src (from Upstate Biotechnology, Lake Placid,
New York), GFP-YAP (gift from Dr. Marius Sudol, Mount
Sinai School of Medicine, New York), GST-p73α (gift
from Dr. Giovanni Blandino, Regina Elena Cancer Insti-
tute, Italy), p53/p73 responsive promoter construct
PG13-Luc (kindly provided by Dr. Bert Vogelstein, Johns
Hopkins University, Baltimore), MDM2-Luc promoter
construct (kind gift from Dr. Moshe Oren, Weizmann
Institute of Science, Israel), and Ipaf-CAT (pCAT-P2) pro-
moter construct, described by us earlier [56]. Different
p73α mutants (tyrosine to phenyl alanine) were made
based on tyrosine phosphorylation sites having high
scores using the NetPhos 2.0 program for SFK target sites
prediction. Y28F-p73α, Y99F-p73α, Y121F-p73α, Y309F-
p73α, Y355-56F-p73α, and Hck mutants, K269E-Hck,
W93A-Hck were made by PCR based site directed muta-
genesis. Plasmids expressing GST-SH3 and GST-mSH3
domain of Hck (amino acids 72-143) were prepared by
cloning the appropriate PCR product into BamH1 and
EcoR1 sites of pGEX2T. All the sequences of the constructs
were confirmed by using an automated DNA sequencer.
The green fluorescence protein (GFP) expression plasmid
pEGFP-C1 was from Clontech. Antibodies to p73 (H-79,
rabbit ployclonal), Hck (rabbit polyclonal), PY20 (mouse
monoclonal), α-tubulin (mouse monoclonal), c-Src (goat
polyclonal), Calnexin (rabbit polyclonal) and GST
(mouse monoclonal) were purchased from SantaCruz
Biotechnology. p73 monoclonal antibody clone 1288 was
from Imgenex. PARP antibody (rabbit polyclonal) was
from Roche.
Construction of vector expressing YAP shRNA
The YAP shRNA expression vector was constructed using
the U6 promoter-based vector essentially as described
[56,71]. The YAP sequence targeted by shRNA (GenBank™
accession NM_006106) was from nucleotides 792-812
(for YPI), 1570-1590 (for YPII) and 1254-1274 (for
YPIII). The YAP sequences targeted by shRNAs were a)
YPI: 5'-GACATCTTCTCGTCAGAGATA-3' b) YPII: 5'-GCT-
GCCACCATGCTAGATAAA-3' and c) YPIII: 5'-CCT-
TAACAGTCGCACCTATCA-3'. The vectors expressing
shRNA of unrelated sequence of the same length were
used as control. All the sequences were confirmed by auto-
mated DNA sequencing.
Immunoprecipitation, GST pull down and Western blot 
analysis
Cos1 cells transfected with indicated plasmids were lysed
in lysis buffer (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 10%
glycerol, 0.5%NP-40, 2 mM EDTA, 2 mM EGTA, 2 mM
PMSF, 2 mM NaF, 2 mM Na3VO4 and protease inhibitor
(Roche Biochemicals) and the extract was incubated with
antibodies overnight at 4°C. The immune complexes
were captured using Protein A/G Plus beads (Santa Cruz)
and washed with buffer (50 mM Tris-Cl pH7.5, 150 mM
Nacl, 10% Glycerol, 0.1% NP-40), the proteins were
eluted by boiling in 3× SDS-sample buffer and separated
on 8% SDS PAGE followed by western blotting with the
required antibodies using ECL detection reagent (Perkin
Elmer).Page 15 of 18
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expressing GST, GST-SH3Hck or GST-mSH3-Hck were
induced by 1 mM isopropyl-β-D-thiogalactopyranosidase
(IPTG) for 4 hours at 37°C. Cells were lysed by addition
of cold PBS containing 1 mM PMSF and protease inhibi-
tors (Roche) and sonicated. To this, 1% Triton-X 100 was
added for 30 minutes at 4°C for solubilization and then
centrifuged to remove insoluble materials. To the super-
natant, Glutathione Sepharose beads (50% slurry) were
added and incubated with end-to-end shaking on Roto-
torque at 4°C for 1 hour. Beads were pelleted, washed
with PBS containing 0.1% TritonX-100 and incubated 6–
8 hours with lysates of Cos1 cells transiently transfected
with indicated plasmids. Bound proteins were eluted by
boiling in 3× SDS sample buffer and subjected to immu-
noblotting.
In-vitro phosphorylation assay
Purified recombinant human Hck (kind gift from Dr.
John Kuriyan, UC Berkeley) was activated for 30 minutes
at 37°C in 20 μl kinase buffer (10 mM TRIS-Cl pH 7.5, 0.5
mM DTT, 10 mM MgCl2, 1 mM MnCl2) containing 20 μM
Na3VO4 and protease inhibitors. Activated Hck (80 nM)
was incubated with GST and GST-p73α in the presence of
3 μCi of γ32P-ATP for 30 minutes at 37°C. The reaction
was terminated by the addition of 3X-SDS sample buffer
followed by boiling for 5 minutes. The proteins were ana-
lyzed by 10% SDS-PAGE and gel was stained with com-
massie blue to visualize expression of proteins and
subsequently dried for phosphor image analysis.
Treatment of cells with mercuric chloride
HL-60 cells were grown in RPMI medium with 10% heat-
inactivated fetal calf serum. These cells were differentiated
by the addition of DMSO (1.25%) for 48 hours. Differen-
tiated cells were subjected to HgCl2 treatment as described
by Robbins et al. [46]. Briefly, the cells were washed with
phosphate-buffered saline and treated with 0.5 mM HgCl2
for 15 minutes at room temperature before the lysates
were subjected to immunoprecipitation with p73 (rabbit
polyclonal) antibody.
Cell fractionation
Transfected Cos1 and HL-60 cells were suspended in cold
buffer A (10 mM Hepes-KOH pH7.9, 1.5 mM MgCl2, 10
mM KCl, 1 mM DTT, 1 mM PMSF, 2 mM Na3V04, 1 mM
EDTA, 1 mM EGTA, protease inhibitors) and incubated
on ice for 15 minutes. Later, NP-40 was added to 1% v/v,
vortexed for 20 seconds and incubated on ice for 10 min-
utes. Cells were pelleted down at 1500 g for 5 minutes at
4°C. Supernatant, which is the cytosolic extract, was re-
suspended in 3× SDS sample buffer and boiled for 5 min-
utes. The nuclear pellet was washed thrice with cold buffer
A (without NP-40) and re-suspended in 3× SDS sample
buffer, boiled for 5 minutes and resolved by 8% SDS
PAGE and subsequently immunoblotted with the
required antibodies.
Apoptosis assays and Immunofluorescence staining
Quantitative analysis of apoptotic cells was carried out as
described previously [36,69]. Cells grown on coverslips
were transfected and processed for immunostaining using
appropriate antibodies for detection of expressing cells.
Cells were mounted in 90% glycerol containing 1 mg/ml
para-phenylenediamine (antifade) and 0.5 μg/ml DAPI
(4'6-diamidino-2 phenylindole) for DNA staining. Cells
showing immunofluorescence staining were counted and
those cells that showed loss of refraction, condensed chro-
matin, apoptotic bodies, cell shrinkage were scored as
apoptotic. At least 200 expressing cells were counted in
each coverslip. The data represent the mean ± S.D. from at
least three independent experiments on duplicate cover-
slips. Background apoptosis was determined by counting
non-expressing cells in the same coverslips. For immun-
ofluorescence staining of endogenous Hck protein, HL-60
cells grown on coverslips were fixed after differentiation
for 24 hours with 10 ng/ml of 12-O-tetradecanoylphor-
bol-13-acetate (TPA) and stained with Hck (rabbit poly-
clonal) primary antibody overnight at 4°C, followed by
anti-rabbit Cy3 secondary antibody incubation for 45
minutes.
Reporter assays
Hela cells were seeded in 24 well plates and transfected
with indicated promoter constructs and expression plas-
mids along with pCMV.SPORT-βGal (Life technologies,
Inc.) Total DNA was kept constant to 400 ng by the use of
pcDNA3. Cells were lysed in reporter lysis buffer
(Promega, Corp.) after 30 hours of transfection and luci-
ferase activity measured by Luciferase repoter assay system
(Promega, Corp). CAT assay was carried out as described
previously [70]. Relative luciferase or CAT activities were
calculated after normalizing with β-galactosidase enzyme
activities.
RT-PCR Analysis
HeLa and SAOS2 cells were transfected with indicated
combination of expression plasmids and after 30 hours of
transfection, total RNA was isolated using Trizol reagent
(Life Technologies, Inc.). Semi-quantitative PCR was car-
ried out as described previously [70]. Appropriate primers
for Ipaf, MDM2, PUMA, 14-3-3σ, Hck, p73 and GAPDH
were used for amplification.
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